Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer
We report a case of oxaliplatin-induced capillary-leak syndrome in a 63-year-old man undergoing his 12th and final cycle of FOLFOX for stage III colorectal cancer. To our knowledge, this is the first case of systemic capillary leak syndrome (SCLS) reported in association with oxaliplatin. Currently, there is no prevention for SCLS. Documenting future cases of SCLS attributed to oxaliplatin is vital, as SCLS is associated with significant morbidity and mortality and no standard treatments beyond supportive care measures exist. Early recognition and diagnosis are therefore essential to improving patient outcomes. (Source: Jo...
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Anderson, B. J., Peterson, L. L. Tags: Case Reports Source Type: research

Fatal pulmonary toxicity due to carfilzomib (Kyprolis™)
We present a case of fatal pulmonary toxicity presumed secondary to carfilzomib. Clinical presentation A 61-year-old male was initially diagnosed with MM in 2003 for which he received multiple treatments. In 2013, he was started on carfilzomib for relapsing MM. After 24 h, the patient developed an acute respiratory distress syndrome for which he needed mechanical ventilation. One week later, patient developed diffuse alveolar hemorrhage and despite aggressive supportive care, the patient died after three weeks. Discussion The temporal relationship between the first exposure to carfilzomib and development of symptoms, and...
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Lataifeh, A. R., Nusair, A. Tags: Case Reports Source Type: research

A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma
Capecitabine is a chemotherapeutic agent which is converted to fluorouracil by thymidine phosphorylase in human body. It is one of the commonly used agents in colorectal and metastatic breast cancers. Hand-foot syndrome is most commonly observed adverse effect of capecitabine; however, it has several adverse cutaneous and mucosal effects. To the best of our knowledge, no case with acneiform eruption has been reported so far. Here, we presented a 54-year-old man with development of capecitabine-related acneiform drug eruption. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Kara, A., Alatas, E., Dogan, G., Celik, S. Y., Tanriverdi, O. Tags: Case Reports Source Type: research

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review
Conclusions Based on the findings from this review of real-world comparative effectiveness studies, risks of FN and FN-related complications were generally lower for prophylaxis with pegfilgrastim versus prophylaxis with short-acting G-CSFs. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Mitchell, S., Li, X., Woods, M., Garcia, J., Hebard-Massey, K., Barron, R., Samuel, M. Tags: Review Articles Source Type: research

Evaluation of empiric antibiotic de-escalation in febrile neutropenia
Conclusions Results of this investigation indicate that broad-spectrum antibiotics can be safely de-escalated to levofloxacin prophylaxis prior to ANC recovery in select patients. This practice may decrease the duration of broad-spectrum antibiotic exposure and associated complications. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Kroll, A. L., Corrigan, P. A., Patel, S., Hawks, K. G. Tags: Review Articles Source Type: research

Comparison of two different formulas for body surface area in adults at extremes of height and weight
Conclusion Guidelines recommend full doses of chemotherapy for patients with curative intent but do not specify which body surface area formula is preferred. Our results imply that the Mosteller equation provides a greater chemotherapy dose, and this difference may be clinically significant in patients who are in the 50th to 95th percentiles for height, weight or both. Further study is necessary to validate these results and determine the impact on patient outcomes. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Fancher, K. M., Sacco, A. J., Gwin, R. C., Gormley, L. K., Mitchell, C. B. Tags: Original Articles Source Type: research

Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle
This study compared comorbidity prevalence among patients with cancer who did and did not develop febrile neutropenia during the first chemotherapy cycle. This case–control study used administrative claims from adult patients with non-Hodgkin lymphoma or breast, lung, colorectal, ovarian, or gastric cancer who received chemotherapy between 2007 and 2012. Each patient who developed febrile neutropenia (case) was matched with up to four patients without febrile neutropenia (controls) by cancer type, metastasis, chemotherapy regimen, age group, and sex. For each comorbidity (identified in the year before chemotherapy be...
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Li, X., Luthra, R., Morrow, P. K., Fisher, M. D., Reiner, M., Barron, R. L., Langeberg, W. J. Tags: Original Articles Source Type: research

Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
This systematic literature review evaluated the clinical efficacy and safety of interventions used in relapsed/refractory follicular lymphoma. Primary efficacy outcomes were objective response rate, progression-free survival and overall survival. Safety endpoints were grade 3/4 toxicities, serious adverse events and withdrawals or deaths due to toxicity. Studies were selected if they were randomized controlled trials reporting on the efficacy or safety of treatments for relapsed or refractory follicular lymphoma, and if outcomes were reported separately from trials that included other lymphoid neoplasms. We used the Bucher...
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Police, R. L., Trask, P. C., Wang, J., Olivares, R., khan, S., Abbe, A., Colosia, A., Njue, A., Sherril, B., Ruiz-Soto, R., Kaye, J. A., Hamadani, M. Tags: Original Articles Source Type: research

Stability of four standardized preparations of methotrexate, cytarabine, and hydrocortisone for intrathecal use
Conclusions Triple intrathecal standardized preparations of methotrexate, cytarabine, and hydrocortisone sodium phosphate are physically and chemically stable at 25℃ for 48 h and at 2–8℃ for 5 days. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - August 9, 2016 Category: Cancer & Oncology Authors: Olmos-Jimenez, R., Espuny-Miro, A., Diaz-Carrasco, M. S., Fernandez-Varon, E., Valderrey-Pulido, M., Carceles-Rodriguez, C. Tags: Original Articles Source Type: research

Two cases of breast carcinoma during pregnancy and review of the literature
We report two cases of patients being diagnosed with breast cancer while being pregnant and treated with surgery and chemotherapy, including anthracyclines, during the second and third trimester of pregnancy. In both reported cases, childbirth was induced before the 37th week of gestation and only one presented low birth weight with no more complications. The echocardiogram monitorization showed normal cardiac function in mothers and fetus. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Pascual, O., Uriarte, M., Agustin, M.-J., Gimeno, V., Larrode, I., Abad, M.-R. Tags: Case Reports Source Type: research

Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia
We describe an 81-year-old relapsed acute promyelocytic leukemia hemodialysis-dependent patient with a pre-existing cardiac condition who was treated with 10 mg arsenic trioxide three times weekly after dialysis. These findings provide support along with the marginal amount of currently published data for an arsenic trioxide dosing regimen in hemodialysis patients. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Perreault, S., Moeller, J., Patel, K., Eyler, R., Pham, T., Russell, K., Podoltsev, N. Tags: Case Reports Source Type: research

A review of blinatumomab, a novel immunotherapy
Blinatumomab is a novel bispecific CD19-directed CD3 T-cell engager recently approved for the treatment of relapsed or refractory Ph-negative acute lymphoblastic leukemia in adults. The drug was approved after a phase II trial in adults with relapsed/refractory disease demonstrated complete remission or hematologic complete remission in 43% of patients within two treatment cycles, of which 40% went on to receive an allogeneic hematopoietic stem cell transplant. In a long-term survival analysis of patients with minimal residual disease after chemotherapy, hematologic relapse-free survival was estimated at 61% at a median of...
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Newman, M. J., Benani, D. J. Tags: Review Articles Source Type: research

A review in the treatment of oncologic emergencies
Conclusion Knowledge of oncology emergencies is critical to the understanding of these emergent syndromes in oncology patients. Each of these disease states requires careful evaluation of the patient’s symptoms, monitoring parameters for conditions and supportive care measures and interventions. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Pi, J., Kang, Y., Smith, M., Earl, M., Norigian, Z., McBride, A. Tags: Review Articles Source Type: research

Biosimilars: Hope and concern
In conclusion, the wish born by the medical community and the society for a more affordable health system triggers the emergence of biosimilars, which could meet that goal if properly regulated. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Emmanouilides, C. E., Karampola, M. I., Beredima, M. Tags: Review Articles Source Type: research

Initiation and preliminary evaluation of an oncology pharmacy training course for staff pharmacists
Discussion Implementation of a formalized OPTC can improve oncology knowledge among staff pharmacists in a community hospital system. This improvement in knowledge is consistent regardless of baseline chemotherapy training. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - June 20, 2016 Category: Cancer & Oncology Authors: Saylor, M. S., Blanchette, L. M., Smith, M. B., Cambron, K., Andricopulos, K., Brown, M. J. Tags: Original Articles Source Type: research